Sermorelin-based stacks (often + Ipamorelin)
Older once-approved GHRH analog used in milder GH stacks
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The combination itself is essentially unstudied. There is no published clinical trial, and no animal study that we can point to, testing sermorelin together with ipamorelin against either peptide alone, so claims of synergy rest on receptor logic rather than on measured outcomes. What evidence exists sits with the components separately. Sermorelin has decades of pharmacology behind it showing that it provokes a pituitary growth hormone pulse, and it was validated well enough as a diagnostic agent to earn approval on that narrow basis, with additional work in children with growth failure. Adult work aimed at aging, body composition, or sleep is thin, small, and mostly old. Ipamorelin was characterised in rodents and in early human pharmacokinetic work as a selective secretagogue that raises growth hormone without the cortisol and prolactin spillover of older compounds, then failed to show enough benefit in postoperative ileus trials to continue development. Neither peptide has demonstrated durable improvement in fat mass, muscle, recovery, or sleep quality in adults with normal pituitary function. Whether the pairing adds anything, or interacts unfavourably, has not been tested.
- FDA
- Sermorelin was FDA-approved in 1997 as Geref, but only as a diagnostic for childhood growth-hormone deficiency, not for anti-aging or fat loss; the brand was voluntarily discontinued in 2008 for business reasons. Today's sermorelin is sold as a compounded product off-label; Ipamorelin is not approved.
- WADA
- Prohibited
Reference only. Not medical advice.
What can go wrong
Sermorelin's risks track the general growth-hormone picture: it raises GH and insulin-like growth factor 1 (IGF-1), which can reduce insulin sensitivity and raise blood sugar, and can cause injection-site reactions, flushing, headache, and fluid retention. The theoretical tumor-growth concern of any IGF-1-raising agent applies, so cancer history is a reason for caution. Because sermorelin's only FDA approval was a short-term pediatric diagnostic use, there is little controlled data on long-term adult use for anti-aging, and none on the ipamorelin combination. Current products are compounded and off-label, so quality and dosing are not guaranteed, and the regimen is prohibited for competitive athletes. Gentler marketing should not be read as safer in the long run, since that has not been demonstrated.
Talk to a clinician before taking this, particularly if you have any history of cancer. The Atlas can tell you what has been studied about Sermorelin-based stacks (often + Ipamorelin). It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
Sermorelin is one of the oldest growth-hormone-releasing hormone (GHRH) analogs: a shortened, 29-amino-acid piece of natural GHRH that still triggers the pituitary gland to release growth hormone (GH). It was FDA-approved in 1997 under the brand Geref, but only as a diagnostic tool to test for growth-hormone deficiency in children, never for anti-aging, fat loss, or adult optimization. The branded product was voluntarily pulled from the market in 2008 for business (not safety) reasons, so today's sermorelin is supplied as a compounded preparation and used off-label. It is often paired with Ipamorelin, a ghrelin-mimicking growth-hormone secretagogue, on the same two-switch logic as the CJC-1295 stack. Sermorelin is marketed as a gentler or more natural GHRH base because it is shorter-acting than newer analogs, though shorter action is not the same as proven safety or benefit. None of these current uses are FDA-approved, and the sermorelin-plus-ipamorelin combination has not been tested in trials. It is promoted by hormone and anti-aging clinics and telehealth platforms, and questioned by endocrinologists who note its only real approval was a narrow pediatric diagnostic use.
once-approved, now compounded
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
Safety in detail
No regulator anywhere has approved sermorelin with ipamorelin as a combination for any purpose, and ipamorelin has no approval of any kind. Sermorelin's only historical approval was diagnostic, and the brand no longer exists, so every current supply is compounded or grey market. United States regulators have scrutinised nominated peptides for compounding and have flagged ipamorelin among substances raising safety concerns, which has narrowed legitimate pharmacy access. Both peptides sit under the peptide hormone and growth factor category of the World Anti Doping Agency list and are banned in and out of competition. Research chemical vials bought online carry the usual grey market problems of unverified identity, potency drift, and endotoxin or solvent contamination. What remains genuinely unknown is whether combining a weak short acting GHRH analog with a ghrelin mimetic changes risk at all, because nobody has measured it.
What people get wrong
Often saidMyth: Sermorelin was FDA-approved, so it is proven for anti-aging.
ActuallyReality: Its only approval (Geref, 1997) was a short pediatric test for growth-hormone deficiency; the brand was discontinued in 2008 and adult anti-aging use is off label.
Often saidMyth: Gentler means safer.
ActuallyReality: Shorter action is marketed as gentle, but long-term safety of adult use and the ipamorelin combination has not been demonstrated.
Who profits, and who pushes back
U.S. Food and Drug Administration
Approved sermorelin (Geref) only as a pediatric GH-deficiency diagnostic; it carries no approval for anti-aging, fat loss, or adult optimization, and the brand was discontinued in 2008.
Endocrinologists (general)
Note that off-label adult anti-aging use rests on little controlled evidence and that gentle framing is not the same as demonstrated safety.
American Medical Association
Advises that compounded, off-label peptide regimens need genuine medical oversight and often lack supporting trial data.
Anti-aging / hormone clinics
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Promote sermorelin as an entry-level GH therapy.
Telehealth peptide platforms
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Sermorelin is a common starter offering.
Wellness / longevity influencers
Framing as natural is common; ties vary.
Where the research comes from
Most of the published research on this comes from one place. 60% of it is from North America. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| North America | 60% |
| Europe | 16% |
| Asia-Pacific | 12% |
| Latin America | 7% |
| Other | 5% |
Research published from: United States.
How we got here
Sermorelin descends directly from the isolation of growth-hormone-releasing hormone in 1982, work credited to Roger Guillemin and Jean Rivier at the Salk Institute and, independently, to Michael Thorner and William Vale's circles, all of whom traced the hormone to pancreatic tumors that caused acromegaly. Chemists soon found that only the first 29 amino acids were needed for activity, giving GRF(1-29)NH2, the molecule later named sermorelin acetate. Serono brought it to market as Geref, approved in the United States in 1997 as a diagnostic and marketed in several European countries, and withdrew it in 2008 for commercial reasons. Ipamorelin came from a different lineage entirely, a Novo Nordisk medicinal chemistry program in the mid 1990s that produced a short pentapeptide ghrelin mimetic, described by Raun and Ankersen and colleagues as a selective growth hormone secretagogue, and later licensed onward without ever reaching approval. The pairing of the two is not traceable to any laboratory or named originator. It emerged from American compounding pharmacies, hormone and longevity clinics, and telehealth prescribers during the 2010s, and spread through bodybuilding forums and clinic marketing copy that borrowed the two-receptor rationale already circulating around CJC-1295.
Sermorelin is a 29-amino-acid fragment of GHRH developed in the 1980s-1990s and approved by the FDA as Geref in 1997, used as a diagnostic for growth-hormone deficiency in children. The branded product was voluntarily discontinued in 2008 for commercial reasons, after which sermorelin re-emerged through compounding pharmacies for off-label adult optimization. Pairing it with ipamorelin is a clinic and telehealth practice rather than a tested protocol; no specific originator of the combination is documented, so any such claim is unvalidated.
- 1990sSermorelin developed as a short GHRH fragment
- 1997FDA approves sermorelin as Geref for pediatric GH-deficiency diagnosis
- 2008Branded Geref voluntarily discontinued for business reasons
- 2010sCompounded sermorelin spreads for off-label adult anti-aging use
- 2024FDA reiterates ipamorelin is unapproved and not compoundable
At a glance
- Sermorelin approved?
- Yes in 1997, brand discontinued 2008
- Approved use
- Pediatric GH-deficiency diagnosis only
- Ipamorelin approved?
- No
- Stack tested together?
- No dedicated trials
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Sermorelin-based stacks (often + Ipamorelin). A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
Sermorelin was approved in the United States in 1997 as Geref, indicated as a diagnostic agent for growth hormone deficiency, and the brand was later discontinued.
U.S. Food and Drug Administration
Peptide hormones and growth factors affecting growth hormone release, including growth hormone releasing hormone analogs and growth hormone secretagogues, are prohibited at all times in sport.
Athletes are warned that growth hormone secretagogues sold as research chemicals are banned and frequently mislabelled or contaminated.
FDA has reviewed peptides nominated as bulk drug substances for compounding under section 503A and has raised safety concerns about several, including ipamorelin, limiting legitimate compounded supply.
U.S. Food and Drug Administration
Ipamorelin was characterised by Novo Nordisk researchers as the first selective growth hormone secretagogue, raising growth hormone in animals without provoking cortisol or prolactin release.
European Journal of Endocrinology (Raun and colleagues, 1998)
Growth hormone releasing hormone was isolated from human pancreatic tumors in 1982, the discovery from which the 29 amino acid sermorelin fragment was derived.
Nature (Guillemin, Rivier and colleagues, 1982)
Growth hormone raising agents increase insulin-like growth factor 1 and can reduce insulin sensitivity, cause fluid retention, joint discomfort and carpal tunnel symptoms.
Endocrine Society clinical practice guideline on adult growth hormone deficiency
No registered clinical trial evaluates sermorelin combined with ipamorelin for anti-aging, body composition, recovery or sleep outcomes.